PLGA from PolySciTech used in development of iron-chelator nanodelivery system as a treatment for cancer

An ideal chemotherapeutic would be a compound which is highly toxic towards cancerous cells but relatively benign towards normal (healthy) cells. Most conventional chemotherapeutics (such as paclitaxel, 5FU, docetaxel, etc.) are not so selective and rather present a generic propensity to prevent growth of both cancerous and healthy cells leading to severe side-effects. Research has identified compounds which present limited toxicity against normal cells while maintaining high efficacy against cancer cells. Recently, researchers at University of Houston and The Pennsylvania State University used PLGA (AP023 and AP165) from PolySciTech (www.polyscitech.com) to create nanoparticles for delivery of a novel anticancer chelator compound Dp44mT. This research holds promise to provide a novel means of treating cancer with limited side effects. Read more: Claire K. Holley, You Jung Kang, Chung-Fan Kuo, Mohammad Reza Abidian, Sheereen Majd “Development and In Vitro Assessment of an Anti-Tumor Nano-Formulation” Colloids and Surfaces B: Biointerfaces 2019, 110481 https://www.sciencedirect.com/science/article/pii/S0927776519306253.

“Highlights: Iron chelator Dp44mT was efficiently encapsulated in PLGA NPs of 50-120 nm size. Dp44mT-NPs were highly toxic to glioma cell lines, U251 and U87, with IC50